Spotlight on Development Leadership Council: Vijendra Nalamothu, PhD

Innovation doesn’t stall because of a lack of ideas.
It stalls because development is hard.

Which is why AID created the Development Leadership Council (DLC), a small group of experienced operators focused on one thing: helping promising dermatology science become real-world products that can reach patients.

The DLC is a committee of founders and industry leaders who’ve taken programs from concept to clinic to market. Their role is practical and action-oriented, offering real development insight, sharpening strategy, and helping early-stage teams avoid costly missteps.

What the DLC Does
The Council supports AID’s mission through three core efforts:

→ Entrepreneur Bootcamp at the Dermatology Innovation Forum (DIF): practical guidance on product development, clinical strategy, regulatory planning, and commercialization.

 → DLC Office Hours: structured, 20-minute, pro-bono consultations every other month via Zoom for early-stage dermatology companies.

→ Networking + collaboration: connecting stakeholders and emerging therapies and technologies that could transform skin health.

This year, the DLC will once again lead the Entrepreneur Bootcamp at DIF, bringing founders into the real mechanics of development that often determine whether innovation reaches patients.

We’re excited to begin introducing the leaders behind this Council!

Vijendra Nalamothu, PhD
Founder & CEO, ApoStrata LLC

Vijendra Nalamothu is a seasoned dermatology drug development executive and entrepreneur with more than 30 years of experience spanning formulation science, translational development, regulatory strategy, and company building.

As Founder & CEO of ApoStrata, and previously Founder & CEO of Tergus Pharma, he has helped advance numerous topical and dermatologic programs from early concept through clinical development and commercialization. His career has focused on bridging the gap between scientific innovation and practical product development.

His expertise spans pre-formulation and formulation science, dermal delivery optimization, IND-enabling strategy, CMC development, and lifecycle positioning in competitive dermatology markets.

Vijendra brings a development-first, execution-oriented lens to the DLC, grounded in real-world constraints like manufacturing scalability, dermal safety, regulatory expectations, and commercial differentiation. He helps early-stage teams build smarter pathways early, so strong science has a real chance of becoming patient impact.

Below, Vijendra shares what drives him, where he sees opportunity in dermatology development, and the advice he returns to most often when working with founders.


What inspired you to join AID’s Development Leadership Council?
I was inspired to join because AID’s mission deeply resonates with the work I’ve been passionate about for years: helping great dermatology science become real-world solutions. The Development Leadership Council is uniquely positioned to bring expert guidance, educational resources, and collaborative support to early-stage innovators - and I wanted to be a part of shaping that support in a practical, impactful way.

DLC provides me with the opportunity to help shape the development ecosystem for dermatology innovators at an earlier stage. Too often, promising ideas struggle not because science is weak, but because the development path is unclear.

AID provides a platform where clinical insight, regulatory awareness, and entrepreneurial thinking come together. Being part of the Development Leadership Council allows me to contribute practical, development-focused guidance that can help emerging companies move more efficiently from concept to clinic - and ultimately to patients.

What knowledge gaps do you see most often in early dermatology product development?
The most common gap I see is underestimating the complexity of topical product development. Many founders focus heavily on mechanism of action but give insufficient attention to formulation science, skin penetration, local tolerability, and regulatory classification strategy.

Another gap is failing to align early CMC decisions with long-term commercial goals. Choices made in early formulation or manufacturing can significantly impact scalability, cost of goods, and even regulatory timelines. Integrating development strategy from day one is critical.

What’s one product development lesson you've learned that you wish more early-stage founders knew?
Start with the end in mind.

Early-stage teams often optimize for proof-of-concept data without clearly defining what a differentiated, approvable, and commercially viable product would look like. Development decisions - formulation platform, clinical endpoints, comparator strategy - should all be made with regulatory approval and market positioning in view.

In dermatology especially, incremental differentiation is rarely enough. You must know early how your product will meaningfully stand out.

You’ve participated in AID’s Entrepreneur Bootcamp, what value do you think it brings to founders or startups?
The Bootcamp provides something that is surprisingly rare: structured, multidisciplinary feedback early in a company’s journey.

Founders benefit from hearing perspectives across preclinical biology, clinical dermatology, regulatory science, manufacturing, and commercialization simultaneously. That integrated feedback can prevent costly missteps and refine both scientific and business strategy. It also accelerates credibility-building with stakeholders and investors.

What kind of informal advice or guidance do you find yourself offering most to emerging founders?
I often advise founders to think holistically and sequentially. Dermatology development is rarely linear, it requires careful integration of formulation science, dermal safety, clinical positioning, and financing milestones.

I also emphasize capital efficiency. Designing studies that generate meaningful, decision-enabling data rather than simply more data is critical. Every experiment should reduce risk in a measurable way.

Looking ahead 5–10 years, what role do you see AID and the Development Leadership Council playing in transforming dermatologic health?
Over the next decade, I believe AID and the Development Leadership Council can serve as a catalyst for smarter, faster dermatologic innovation.

By fostering education, mentorship, and cross-disciplinary collaboration, the Council can help reduce development inefficiencies and elevate the overall quality of early-stage programs entering the clinic.

If we can shorten development cycles, improve translational rigor, and better align scientific innovation with patient needs, the impact on dermatologic health will be significant.

Ready to check out all that the DLC has to offer?
Learn more about our council here.

Register for the Dermatology Innovation Forum 2026:
https://advancing-derm.org/platform/conferences/dermatology-innovation-forum-2026/